Prashanth Gopalakrishna

机构：Pfizer (United States)

发表论文 43 篇 · 总被引 1010 次 · h-index 14

代表论文

• Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses (2017 · Journal of Hematology & Oncology · 被引 307)
• Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study (2018 · Journal of Cancer Research and Clinical Oncology · 被引 145)
• Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy (2013 · Breast Cancer Research and Treatment · 被引 67)
• Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer (2018 · Clinical Cancer Research · 被引 66)
• Ruxolitinib is an effective treatment for CALR ‐positive patients with myelofibrosis (2015 · British Journal of Haematology · 被引 49)
• The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis (2015 · Experimental Hematology and Oncology · 被引 44)